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ABSTRACT
Objective Familial hypercholesterolaemia (FH) is 
characterised by elevated low- density lipoprotein (LDL)- 
cholesterol and increased risk of cardiovascular disease. 
However, FH remains substantially underdiagnosed and 
undertreated. We employed a two- stage pragmatic 
approach to identify and manage patients with FH in 
primary healthcare.
Methods Medical records for 232 139 patients who 
attended 15 general practices at least once in the previous 
2 years across five Australian States were first screened for 
potential risk of FH using an electronic tool (TARB- Ex) and 
confirmed by general practitioner (GP) clinical assessment 
based on phenotypic Dutch Lipid Clinic Network Criteria 
(DLCNC) score. Follow- up GP consultation and management 
was provided for patients with phenotypic FH.
Results A total of 1843 patients were identified 
by TARB- Ex as at potential risk of FH (DLCNC score 
≥5). After GP medical record review, 900 of these 
patients (49%) were confirmed with DLCNC score 
≥5 and classified as high- risk of FH. From 556 patients 
subsequently clinically assessed by GPs, 147 (26%) 
were diagnosed with phenotypic FH (DLCNC score 
>6). Follow- up GP consultation and management 
for 77 patients resulted in a significant reduction in 
LDL- cholesterol (−16%, p<0.01). A higher proportion 
of these patients attained the treatment target of 50% 
reduction in LDL- cholesterol (74% vs 62%, p<0.001) 
and absolute levels of LDL- cholesterol goals compared 
with baseline (26% vs 12%, p<0.05).
Conclusions A pragmatic approach integrating electronic 
medical record tools and clinical GP follow- up consultation 
is a feasible method to identify and better manage patients 
with FH in the primary healthcare setting.
Trial registration number 12616000630415.
INTRODUCTION
Familial hypercholesterolaemia (FH) is a codom-
inantly inherited lipid disorder with over 90% 
penetrance, principally due to mutations in the 
low- density lipoprotein (LDL) receptor that causes 
marked elevations in plasma LDL- cholesterol.1 2 FH 
has a prevalence of 1 in 250 in the general popu-
lation.2–4 Lifetime exposure to elevated LDL- 
cholesterol puts patients at significantly higher 
risk of atherosclerotic cardiovascular disease 
(ASCVD).1–3 Despite increasing awareness of the 
condition,2 5 6 FH remains underdiagnosed and 
undertreated due to a lack of effective screening 
and management strategies.2 5–8
FH guidelines support improved primary care- 
based detection and management.2 5 6 With 88% 
Australians attending a general practitioner (GP) 
annually,9 GPs are ideally placed to assist with 
FH detection and management.10–12 To date, little 
attention has been given to such an approach in 
general practice.13
While genetic testing for pathogenic mutations 
provides a definitive diagnosis of FH,14 assessment 
tools, such as the Dutch Lipid Clinic Network 
Criteria (DLCNC), the Simon Broome, FAMCAT 
and Make Early Diagnosis to Prevent Early 
Deaths criteria, are widely employed in the clin-
ical setting.5 6 Of these, the DLCNC score remains 
the most popular diagnostic method in Australia.6 
FH screening of electronic health records (EHRs) 
in primary care can identify patients with high 
DLCNC score.15–17 We have previously validated 
a time and cost- effective electronic screening tool 
(TARB- Ex) to help identify potential risk patients 
based on their DLCNC score.16 The clinical value 
of TARB- Ex in facilitating FH detection in general 
practice, followed by clinical care by GPs, requires 
further demonstration.
Treatment of elevated LDL- cholesterol is the 
cornerstone of FH management.5 18 GP- managed 
lowering of LDL- cholesterol levels in patients with 
FH through lifestyle modification and drug therapy 
is critical for reducing risk of ASCVD. The effec-
tiveness of this approach has not been widely inves-
tigated in general practice.
We employed a pragmatic approach to detect 
and manage FH index cases in primary care. We 
evaluated the yield of detection of patients with FH 
based on the TARB- Ex tool and clinical follow- up 
in 15 Australian general practices. We also inves-
tigated the effectiveness of GP- managed care in 




The study protocol has been published and involves 
a pragmatic approach using the real- life clinical 
infrastructure of Australian general practice.19 
Briefly, we carried out a non- randomised, non- 
controlled preintervention and postintervention 
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study to investigate the effectiveness of a two- stage screening 
programme on the detection and follow- up management of FH 
in general practice. The study was conducted between 2016 and 
2020 in 15 general practices: 5 in Western Australia (WA); 5 in 
New South Wales (NSW)—1 withdrew prior to completion; 3 in 
Queensland (QLD); 1 in Victoria (VIC) and 2 in Tasmania (TAS). 
Eligible practices were Royal Australian College of General Prac-
titioners accredited, used Best Practice software (ie, SNOMED 
coding system for recording clinical encounters),19 expressed 
interest in the research topic and included GPs, practice nurses 
(PNs) and managers willing to be trained and perform DLCNC 
assessment. The TARB- Ex data extraction tool, validated to 
operate on Best Practice software, uses an in- built algorithm that 
corrects LDL- cholesterol levels among patients on lipid- lowering 
medications (statins with or without ezetimibe).16
Study procedure
The study protocol included four major steps, namely educa-
tion and training, electronic screening and clinical assessment, 
follow- up consultation and management as well as patient and 
public involvement. Full details are available as online supple-
mental file.
Statistical analysis
Statistical analyses were performed using SPSS V.25 (IBM, 
Armonk, New York, USA). Descriptive analyses are presented 
as mean±SD or number (%) where applicable. We used Shapiro- 
Wilk test to determine whether variables were normally distrib-
uted. Clinical and biochemical variables between patients who 
completed and did not complete the follow- up consultation 
and management were compared using independent t- test or 
χ² test. Yields of patients identified with FH were described 
as the number of patients required to detect one new case at 
different stages in the screening process. Effects of GP manage-
ment on plasma LDL- cholesterol between baseline (the closest 
treated/untreated LDL- cholesterol level to the first consultation) 
and lowest follow- up LDL- cholesterol following GP consulta-
tion(s), were recorded and compared using Wilcoxon signed- 
rank test. We carried out mixed model repeated measures 
analysis to test whether the changes in plasma LDL- cholesterol 
during follow- up period was significant. Changes in proportion 
of patients reaching LDL- cholesterol targets between baseline 
and follow- up were compared using McNemar’s test. Statistical 
significance was defined as p<0.05.
RESULTS
TARB-Ex screening and medical record review
Figure 1 shows patient flow for TARB- Ex screening, manual 
record review, clinical assessment and follow- up consultations. 
A total of 232 139 patients (minimum one visit in past 2 years) 
attended the practices over study period. Of these, 67 932 
patients (29%) were identified by TARB- Ex with a recorded 
LDL- cholesterol measurement. A total of 1843 patients had 
DLCNC score ≥5 and classified as potential risk of FH. The 
prevalence of patients at potential risk was 1:126 of total 
patients (0.79%) and 1:37 for the subgroup of patients (2.7%) 
with a cholesterol measurement (1843 out of 232 139 patients 
and 67 932 patients, respectively). Of 1843 patients with manual 
medical record reviews by GPs, 900 (49%) were confirmed with 
DLCNC score ≥5 and classified as high- risk. The prevalence of 
patients at high- risk of FH was 1:256 of total patients and 1:75 
for the subgroup of patients with a cholesterol level recorded 
(900 out of 232 139 patients and 67 932 patients, respectively).
Clinical assessment of potential cases of FH
A total of 678 patients with high- risk, potential FH (75%) with 
DLCNC score ≥5 were invited to attend a GP review. The 
remaining 222 patients (25%) were unable to be contacted. Of 
the 678 high- risk patients, a detailed clinical assessment was 
undertaken by GPs on 556 patients, while 122 patients did not 
attend. A total of 147 patients with DLCNC score ≥6 were diag-
nosed as phenotypic FH.
Yields of identifying patients with FH
Figure 2 shows yields of 147 patients identified with pheno-
typic FH at different stages in the study. The yield was 1 in 462 
from patients with cholesterol measurement (0.2%) and 1 in 13 
from those at potential risk as screened by TARB- Ex (8.0%). GP 
medical record review identified/classified one new case of FH 
for every six patients at high- risk (16%) while clinical assessment 
identified one new case for every four patients who attended GP 
review (26%).
Follow-up consultation and management
A total of 133 patients with phenotypic FH consented to the 
study (figure 1). These included 96 newly diagnosed index cases 
from TARB- Ex screening, 27 patients with existing FH and 10 
patients with incidental FH diagnosis (new cases to the prac-
tice and/or identified by GP clinical assessment via usual care, 
Figure 1 Flow diagram for TARB- Ex screening, medical record review, 
clinical assessment and follow- up consultation. DLCNC, Dutch Lipid 
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not through initial TARB- Ex extraction). All consented patients 
were invited to join the FH Australasia (FHAN) Registry with 
106 included by 30 November 2020.
Table 1 shows baseline clinical and biochemical character-
istics of the 133 patients. They were on average middle- aged, 
overweight, normotensive and mildly hypercholesterolaemic. 
58 patients (44%) had at least one clinical CVD event while 
113 (85%) had a family history of premature coronary artery 
disease (CAD). A total of 71 patients (53%) were current 
(n=19) or ex- smokers (n=52). A total of 87 patients were on 
statin alone (65%), 7 on ezetimibe alone (5.3%) and 25 on 
both (19%). The average equivalent dose of atorvastatin was 
50.9±26.4 mg/day. The percentage of patients attaining treat-
ment target of 50% reduction in LDL- cholesterol from their 
highest LDL- cholesterol prior to treatment was 65%. The 
percentage achieving the absolute target of LDL- cholesterol 
recommended was 16% (<2.6 mmol/L and <1.8 mmol/L for 
primary and secondary prevention, respectively).18
From 133 consented patients, 77 attended minimum 1 
follow- up GP consultation and had LDL- cholesterol measure-
ment. The remaining 56 patients did not complete the study 
either failing to attend follow- up consultations (n=29) and/
or had no follow- up lipid profile (n=44). There were no 
significant differences in clinical and biochemical variables 
between the two groups at recruitment (table 1). Of the 77 
patients, 48 had minimum 2 follow- up consultations and 28 
had three. The average follow- up period was 221±44 days. 
A total of 359 first- degree or second- degree relatives were 
identified from 77 FH index cases (ie, 4.7 relatives/case), as 
needing cascade screening.
During follow- up, 28 patients (36%) commenced statin 
therapy (n=5) or changed to higher dose of existing statin (n=22) 
or received higher potency statin (n=1). The corresponding 
equivalent dose of atorvastatin increased from 34.3 mg/day to 
61.1 mg/day. A total of 20 patients (26%) received GP advice to 
modify lifestyle factors and 4 (5.2%) required specialist referral. 
Patients failing to attain LDL- cholesterol target at baseline (50% 
LDL- cholesterol reduction) were more likely to receive higher 
intensity treatment than those reaching treatment target (50% vs 
29%, p=0.09); however, this did not reach significance. Among 
11 patients receiving GP lifestyle advice alone, plasma concentra-
tions of total cholesterol (6.2±0.6 mmol/L vs 5.8±0.5 mmol/L) 
and LDL- cholesterol (3.6±0.5 mmol/L vs 3.4±0.4 mmol/L) did 
not significantly differ from baseline (p>0.05 for both).
Figure 3 shows plasma concentration of total cholesterol, 
LDL- cholesterol, high- density lipoprotein (HDL)- cholesterol 
and triglycerides at baseline and after follow- up. There were 
significant reductions in plasma total cholesterol (−9.4%) and 
LDL- cholesterol (−16%) levels in patients with GP consulta-
tion/ management compared with baseline (p<0.01). Patients 
changed to higher dose of existing statin or receiving higher 
potency statin had greater reduction in LDL- cholesterol levels 
compared with those without (−24% vs –9.2%, p<0.05; 
figure 4). Of 77 patients who completed the study, 54 had one 
follow- up plasma LDL- cholesterol assessment, and 18 had 2 and 
5 had 3 assessments. Using mixed model repeated measures anal-
ysis, the reduction in plasma LDL- cholesterol levels was signifi-
cant during follow- up period (p<0.01). The individual changes 
in plasma LDL- cholesterol levels following GP consultation are 
shown in online supplemental figure 1.
A higher proportion of patients achieved treatment target of 50% 
LDL- cholesterol reduction after receiving GP management (74% 
vs 62%, p<0.001). More GP- managed patients with FH attained 
the absolute levels of LDL- cholesterol target goals compared with 
Figure 2 Yield of detection of 147 patients with phenotypic familial 
hypercholesterolaemia. FH, familial hypercholesterolaemia; GP, general 
practitioner.
Table 1 Baseline clinical and biochemical characteristics of the 133 






Number of participants 133 77 56
Age 61.4±13.9 60.8±12.2 62.4±15.9
Male gender, n (%) 51 (38.3) 32 (41.6) 19 (33.9)
Caucasian ethnicity, n (%) 125 (93.9) 71 (92.2) 54 (96.4)
Weight, kg 81.4±18.5 82.4±20.1 79.9±15.8
Body mass index, kg/m2 29.4±7.2 29.1±6.1 29.9±8.7
Systolic blood pressure, mm Hg 130±16.8 128±16.8 132±15.2
Diastolic blood pressure, mm Hg 75.5±11.3 74.8±11.2 76.6±11.4
Personal history of ASCVD 58 (43.6) 30 (39.0) 28 (50.0)
Family history of ASCVD 113 (85.0) 68 (88.3) 45 (80.4)
Tendon xanthomas 2 (1.5) 2 (2.6) 0 (0)
Arcus cornealis 11 (8.3) 9 (11.7) 2 (3.6)
Smoking (19 current and 52 ex- 
smokers)
71 (53.4) 43 (55.8) 28 (50.0)
Type 2 diabetes 9 (6.8) 6 (7.8) 3 (5.4)
Obesity (body mass index >30 kg/m2) 42 (31.5) 24 (31.2) 18 (32.1)
Shared care with specialists 30 (22.6) 21 (27.2) 9 (16.1)
On statin 115 (86.5) 67 (87.0) 48 (85.7)
On ezetimibe 33 (24.8) 68 (24.7) 14 (25.0)
Phenotypic DLCNC score 7.7±1.9 7.8±2.1 7.5±1.7
Triglyceride, mmol/L 1.7±0.9 1.7±0.9 1.7±1.0
Total cholesterol, mmol/L 6.1±2.0 6.3±2.1 5.7±1.9
HDL- cholesterol, mmol/L 1.4±0.4 1.4±0.4 1.5±0.4
LDL- cholesterol, mmol/L 3.9±1.9 4.1±1.9 3.5±1.8
Non- HDL- cholesterol, mmol/L 4.6±1.9 4.8±1.9 4.2±1.8
Attainment LDL- cholesterol treatment target†
  By 50% reduction 86 (64.7) 48 (62.3) 38 (67.9)
  By absolute concentration 21 (15.9) 9 (11.7) 12 (21.4)
Values represented as mean±SD or number (%).
*There were no significant differences in clinical and biochemical variables between 
the two groups at recruitment; p>0.05 for all.
†Target absolute value of LDL- cholesterol refers to an absolute level of LDL- 
cholesterol (ie, <2.6 mmol/L or <1.8 mmol/L for primary and secondary prevention.18
ASCVD, atherosclerotic cardiovascular disease; DLCNC, Dutch Lipid Clinic Network 
Criteria; HDL, high- density lipoprotein; LDL, low- density lipoprotein.
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their baseline (26% vs 12%, p<0.05) (figure 5). More specifically, 
15 patients with baseline LDL- cholesterol above treatment cut- off 
attained LDL- cholesterol target after follow- up consultation(s).
DISCUSSION
This study provides a pragmatic approach for improving the detec-
tion and management of FH in general practice. Using a two- stage 
process combining screening electronic data with subsequent clin-
ical assessment, we diagnosed 147 patients with phenotypic FH 
from a total of 232 139 patients attending 15 GP clinical practices 
across five Australian States. Importantly, GP management was 
effective in lowering LDL- cholesterol levels for patients at higher 
ASCVD risk.
Previous studies
Several approaches have attempted to detect patients with FH 
in primary care.11 15–17 20–23 including four studies employing 
electronic data extraction tools.15–17 23 Using combined 
computer- based and notes- based searches, Grey et al identified 
9 new cases of phenotypic FH (DLCNC score >5) in single 
general practice of 12 100 registered patients.15 Weng et al used 
FAMCAT, including nine diagnostic risk variables, to identify 
patients with high FH risk following clinical assessment using 
specific diagnostic criteria or genetic testing with a predictive 
accuracy of 86%.23 Using a SQL- based electronic screening tool 
(TARB- Ex), Troeung et al identified 32 patients at potential FH 
risk (DLCNC score >5) in one practice of 3708 active patients.16 
Kirke et al used data extraction software (Canning Tool) to 
screen for patients with FH indicators in 2 regional practices 
of 41 100 EHRs and identified 32 patients with phenotypic 
FH (DLCNC score >5) after follow- up clinical assessment by 
trained FH nurse.17 These small scale pilot studies (1–2 general 
practices) did not examine the effectiveness of subsequent GP 
management. In a study of 32 patients diagnosed with possible 
FH, Weng et al found that primary care intervention resulted in 
small and non- significant reductions in total cholesterol (−2%) 
and LDL- cholesterol (−3%).24 Our research has extended these 
studies to an Australia- wide primary care- based programme for 
detection and management of new FH index cases.
Figure 3 Plasma lipid concentrations in the 77 patients at baseline 
and after GP consultations. GP, general practitioner; HDL, high- density 
lipoprotein; LDL, low- density lipoprotein.
Figure 4 Percentages changes in plasma concentration of LDL- 
cholesterol in patients with or without changing to a higher intensity 
statin LDL- cholesterol lowering treatment. *Increased intensity of 
treatment refers to 28 patients started on stain therapy (n=5) or 
changed to a higher dose of existing stain (n=22) or received a higher 
potency statin (n=1) for LDL- cholesterol lowering. LDL, low- density 
lipoprotein.
Figure 5 Attainment of LDL- cholesterol by a 50% reduction from 
highest untreated level (A) and an absolute target value for primary 
and secondary prevention (B) in the 77 patients at baseline and after 
GP consultation. Baseline value refers to the closest treated/untreated 
LDL- cholesterol level to the first consultation. Target absolute value of 
LDL- cholesterol refers to an absolute level of LDL- cholesterol (ie, <2.6 
mmol/L or <1.8 mmol/L for primary and secondary prevention).18 GP, 
general practitioner; LDL, low- density lipoprotein.
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Detection of patients with phenotypic FH
Despite identifying 147 patients with phenotypic FH following 
GP assessment, over 30% did not undergo clinical assessment 
because they were not contactable or did not attend. Despite 
efforts by practices to invite patients at high- risk of FH, low 
capture rate was constrained by real- world clinical care priority 
setting. Lack of awareness and knowledge of FH among patients/
families may explain their underappreciation of the need 
to attend such assessment.5 6 8 Further efforts are required to 
improve public awareness of FH.
Effectiveness of GP management in FH
Given the lifelong risk for ASCVD associated with FH, inten-
sive LDL- cholesterol reduction is required for these patients. 
While 65% of consented patients attained 50% LDL- cholesterol 
reduction from untreated highest LDL- cholesterol levels, only 
16% attained guideline recommendation of absolute LDL- 
cholesterol target level of <2.6 mmol/L (or <1.8 mmol/L in 
adults with ASCVD).5 This observation is consistent with anal-
yses from the FHAN and SAFEHEART registries where only 
25% and 11% of patients with FH reached the LDL- cholesterol 
treatment target, respectively.7 25 Our study identified a similar 
treatment gap in the primary care setting where currently recom-
mended LDL- cholesterol targets are difficult to achieve for most 
patients with FH, probably due to inadequate treatment with 
high- intensity statins and other medications for persistent high 
LDL- cholesterol.
Evidence supports short- term and long- term benefits of 
lowering LDL- cholesterol for the prevention of ASCVD among 
patients with FH.5 6 18 Our research found that implementing 
a pragmatic intervention plan by GPs (statin/ezetimibe medica-
tion±lifestyle advice) resulted in significant reduction in LDL- 
cholesterol levels. As expected, the greatest LDL- cholesterol 
reduction was observed in patients changed to higher intensity 
LDL- cholesterol lowering treatment, resulting in an approximate 
1.3 mmol/L decrease in LDL- cholesterol. More importantly, the 
achieved absolute LDL- cholesterol target level reduction could 
translate into a 20%–25% relative reduction of global CV risk.18 
In addition, we found that the proportion of patients with FH 
achieving treatment targets significantly increased with GP 
follow- up management. While the results were encouraging, 
there remained 74% of patients with FH failing to reach the 
recommended absolute LDL- cholesterol targets. This under-
scores the need for more intensive GP management including 
additional specialist support for greater use of more potent 
cholesterol- lowering medication (such as proprotein conver-
tase subtilisin/kexin type 9 inhibitors) if applicable. Enhancing 
GP knowledge of FH and/or awareness of current guidelines 
to improve the effectiveness of FH management merits further 
investigation.5 6
More than 40% of patients with FH did not complete the 
study mainly by failing to attend follow- up consultations. It is 
difficult to control patient motivation in primary care where 
a myriad of competing factors including consultation costs 
take precedence in the mind of the patient. This underscores 
potential barriers to effective FH management from the patient 
perspective, including knowledge of FH and perception of 
ASCVD risk.26 Increasing community awareness of the impor-
tance of elevated cholesterol as a risk factor for ASCVD, as well 
as focused education (especially smoking cessation) for patients/
families with FH about this disorder and their high risk of 
ASCVD, is critically important.
Strengths and limitations
Our study’s strength includes the use of a two- stage process to 
facilitate an improved detection rate of FH. We used a pragmatic 
approach to investigate the effect of follow- up GP consultation 
and management of plasma LDL- cholesterol levels in primary 
care and piloted the inclusion of patients in the FH registry.5 6
Our study also has limitations. The accuracy of TARB- Ex 
extractions might have been affected by non- compliance with 
statin to correctly estimate untreated LDL- cholesterol, together 
with other factors, including poor quality of medical informa-
tion in practice EHRs (eg, family history of CAD) and the pres-
ence of secondary hypercholesterolaemia, including cholestasis, 
nephrotic syndrome, steroid use, hypothyroidism. Whether use 
of age- specificity of untreated LDL- cholesterol levels or another 
case- finding algorithm could improve specificity for the detec-
tion of FH merits further investigation.27 We cannot exclude 
the possibility that detection of FH could be missed in patients 
with DLCNC score of 3–4 (possible FH) but this would require 
assessment of a much larger sample.
The low numbers undertaking follow- up consultations reflect 
reality in clinical practice and are acknowledged as potential 
bias in our findings. The pragmatic design of our study also did 
not allow us to employ a placebo- controlled design to study 
the effects of GP management on plasma LDL- cholesterol in 
general practice. Hence, our findings need to be interpreted 
with caution. Despite GPs and PNs receiving education and 
training on FH, poor knowledge and awareness of the condi-
tion might have impacted detection yield.28 Other barriers, 
including limited time and resources for training and diag-
nostic assessment, also need to be considered. The follow- up 
period for some was relatively short (~7 months) and might 
not allow enough time to determine the programme’s effec-
tiveness. Variations in compliance with lifestyle advice and 
medications between patients might have confounded the 
analysis and merits further investigation. While we identified 
359 close relatives as potential targets, cascade testing was not 
formally implemented. The logistics of undertaking cascade 
testing in primary care needs further exploration with lack of 
practice infrastructure seen as a major barrier. The involve-
ment of specialist lipid clinics in family cascade testing through 
GP referrals is available in major cities but further extension 
should be considered. Our study did not involve genetic testing 
and numbers of confirmed phenotypes with a potential muta-
tion remain unknown. Children and people under 18 years of 
age were not included in the TARB- Ex search and represent 
another potential missed opportunity to improve FH detection. 
Whether the improvement in LDL- cholesterol level and change 
in treatment was due to the behaviour change in patients after 
their FH diagnosis and face- to- face consultations with GPs, 
merits further investigation.
CONCLUSION AND FUTURE DIRECTIONS
FH is a major public health problem with a need to address the 
gap in care.2 5–7 Early detection and treatment of FH is recom-
mended to reduce the risk of ASCVD.2 5 6 However, most affected 
individuals remain undiagnosed and undertreated. While cascade 
screening is the most cost- effective means of finding new index 
cases,29 it requires a targeted approach to increase their identifi-
cation. Using a pragmatic approach with existing infrastructure, 
our study shows a nationwide, two- stage screening programme 
based on general practice is feasible. The study also highlights the 
importance of follow- up consultation and management by GPs 
in improving treatment in high- risk patients. Further research 
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into improving compliance with lifestyle advice and medications 
merits investigation.
Several strategies may enhance detection of FH, including 
universal screening of children, child- parent cascade testing, and 
screening of patients presenting to coronary care units.5 6 10 22 
There is a need to integrate our general practice approach with 
these strategies to further enhance the detection of FH, partic-
ularly in the young. Other challenges include the integration 
of GP and specialist services.13 30 Health economic evaluation 
and patient perceptions (ie, outcomes and experience) of our 
approach will be reported separately. The systematic imple-
mentation of a primary case- based cascade testing programme 
among close relatives of newly identified FH index cases also 
merits investigation.
Key messages
What is already known on this subject?
 ► Familial hypercholesterolaemia (FH) is an underdiagnosed 
and undertreated inherited disorder largely due to a lack of 
effective screening and management strategies for improving 
care of FH.
 ► General practice is increasingly recommended as an optimal 
setting for FH screening and management.
What might this study add?
 ► Our study provides a pragmatic approach to identify 147 
patients with FH from a total of 232 139 patients attending 
15 general practices across five Australian States.
 ► We also demonstrate that follow- up consultation and 
management is effective in lowering LDL- cholesterol levels 
by 16% as a consequence of increased intensity in statin 
therapy and we identified 359 first- degree and second- degree 
relatives from FH index cases suitable for cascade screening.
How might this impact on clinical practice?
 ► A pragmatic approach integrating electronic medical record 
tools and clinical GP follow- up consultation is a feasible 
method to identify and better manage patients with FH in 
primary healthcare.
 ► Improved infrastructure in primary care is needed to 
undertake cascade testing of close relatives of FH index 
patients.
Author affiliations
1General Practice and Primary Health Care Research Unit, School of Medicine, The 
University of Notre Dame Australia, Fremantle, Western Australia, Australia
2General Practitioner, Mosman Park Medical Centre, Perth, Western Australia, 
Australia
3Medical School, The University of Western Australia, Perth, Western Australia, 
Australia
4Launceston Clinical School, University of Tasmania, Launceston, Tasmania, Australia
5Mackay Clinical School, James Cook University, Mackay, Queensland, Australia
6School of Medicine, Deakin University, Geelong, Victoria, Australia
7School of Medicine, The University of Notre Dame Australia, Sydney, New South 
Wales, Australia
8School of Population and Global Health, The University of Western Australia, Perth, 
Western Australia, Australia
9Department of Chemical Pathology, Royal Prince Alfred Hospital, New South Wales 
Health Pathology, Sydney, New South Wales, Australia
10Division of General Practice, The University of Western Australia, Perth, Western 
Australia, Australia
11School of Medicine, The University of Notre Dame Australia, Fremantle, Western 
Australia, Australia
12Lipid Disorders Clinic, Cardiometabolic Service, Department of Cardiology and 
Internal Medicine, Royal Perth Hospital, Perth, Western Australia, Australia
Acknowledgements We thank the staff and patients at the participating general 
practices for their assistance in the study. Also, to T Grace, L Troeung, W Chan She 
Ping- Delfos, L Hall, V Foulkes- Taylor, K Holloway- Kew, D Campbell and S Wilks for 
project management support and to M Bulsara for statistical advice.
Contributors TB conceived, designed and conducted the study, provided 
methodological support including practice visits, conducted the analyses, interpreted 
the results and wrote, read and edited the manuscript. DC conducted the analyses, 
interpreted the results and wrote, read and edited the manuscript. JR, CHeal, GG, 
CHesp contributed to study design, conducted the study, read and edited the 
manuscript. CVG, CC, BS helped conduct the study, read and edited the manuscript. 
DAR, IL, AV and JP contributed to study conception and design, read and edited the 
manuscript. DS and GW contributed to study conception and design, interpretation 
of results, provided specialist support, read and edited the manuscript.
Funding The study was supported by the National Health Medical Research Council 
(NHMRC) partnership grant (GNT1142883). Royal Perth Hospital Medical Research 
Foundation provided FH registry funding. Mackay Base Hospital Research Funding 
provided funding for the Queensland arm. WATHN provided support for community 
conversations in WA. The Western Australia Department of Health provided funding 
support for study analysis. The WA & QLD study arms were supported by funding 
from Sanofi- Aventis Australia Pty Ltd (Sanofi). The NSW arm was supported by 
funding from Amgen Australia Pty Ltd.
Disclaimer Neither Sanofi nor Amgen were involved in the design, collection, 
analysis, interpretation or reporting of the study, but were given the opportunity to 
review the manuscript prior to publication. The decision to submit for publication 
was made independently by the authors. Sanofi and Amgen will be allowed access to 
all de- identified data from the study for research and audit purposes, if requested.
Competing interests TB has received honoraria for lectures or research grants 
from Amgen and Sanofi. DAR has received research grants from Sanofi and WA 
Department of Health, and travel and accommodation support from Amgen. GW has 
received honoraria for lectures and advisory boards or research grants from Amgen, 
Arrowhead, AstraZeneca, Esperion, Kowa, Novartis, Regeneron and Sanofi.
Patient consent for publication Not required.
Ethics approval The study was approved by the Human Research Ethics 
Committee of The University of Notre Dame Australia (Protocol ID 0 16 067F).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available on reasonable request.
Supplemental material This content has been supplied by the author(s). It 
has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have 
been peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Tom Brett http:// orcid. org/ 0000- 0003- 4723- 742X
Dick C Chan http:// orcid. org/ 0000- 0001- 7658- 5197
REFERENCES
 1 Borén J, Chapman MJ, Krauss RM, et al. Low- Density lipoproteins cause 
atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic 
insights: a consensus statement from the European atherosclerosis Society consensus 
panel. Eur Heart J 2020;41:2313–30.
 2 Representatives of the Global Familial Hypercholesterolemia Community, Wilemon 
KA, Patel J, et al. Reducing the clinical and public health burden of familial 
hypercholesterolemia: a global call to action. JAMA Cardiol 2020;5:217–29.
 3 Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of familial hypercholesterolemia 
among the general population and patients with atherosclerotic cardiovascular 
disease: a systematic review and meta- analysis. Circulation 2020;141:1742–59.
 4 Watts GF, Shaw JE, Pang J, et al. Prevalence and treatment of familial 
hypercholesterolaemia in Australian communities. Int J Cardiol 2015;185:69–71.
 5 Watts GF, Gidding SS, Mata P, et al. Familial hypercholesterolaemia: evolving 
knowledge for designing adaptive models of care. Nat Rev Cardiol 2020;17:360–77.
 on S
eptem














7Brett T, et al. Heart 2021;0:1–7. doi:10.1136/heartjnl-2020-318813
Cardiac risk factors and prevention
 6 Watts GF, Sullivan DR, Hare DL, et al. Integrated guidance for enhancing the care of 
familial hypercholesterolaemia in Australia. Heart Lung Circ2021;30:324–49.
 7 Pang J, Sullivan DR, Hare DL, et al. Gaps in the care of familial hypercholesterolaemia 
in Australia: first report from the National registry. Heart Lung Circ. In Press 
2021;30:372–9.
 8 Alonso R, Perez de Isla L, Muñiz- Grijalvo O, et al. Barriers to early diagnosis and 
treatment of familial hypercholesterolemia: current perspectives on improving patient 
care. Vasc Health Risk Manag 2020;16:11–25.
 9 Australian Institute of Health and Welfare. Medicare- subsidised GP, allied health and 
specialist health care across local areas: 2013–14 to 2018–19. Available: https://
www. aihw. gov. au/ reports/ primary- health- care/ medicare- subsidised- health- local- 
areas- 2019/ contents/ introduction [Accessed 27 Oct 2020].
 10 Brett T, Qureshi N, Gidding S, et al. Screening for familial hypercholesterolaemia 
in primary care: time for general practice to play its part. Atherosclerosis 
2018;277:399–406.
 11 Bell DA, Kirke AB, Barbour R, et al. Can patients be accurately assessed for familial 
hypercholesterolaemia in primary care? Heart Lung Circ 2014;23:1153–7.
 12 Vickery AW, Bell D, Garton- Smith J, et al. Optimising the detection and management 
of familial hypercholesterolaemia: central role of primary care and its integration with 
specialist services. Heart Lung Circ 2014;23:1158–64.
 13 Brett T, Watts GF, Arnold- Reed DE, et al. Challenges in the care of familial 
hypercholesterolemia: a community care perspective. Expert Rev Cardiovasc Ther 
2015;13:1091–100.
 14 Sturm AC, Knowles JW, Gidding SS, et al. Clinical genetic testing for familial 
hypercholesterolemia: JACC scientific expert panel. J Am Coll Cardiol 
2018;72:662–80.
 15 Gray J, Jaiyeola A, Whiting M, et al. Identifying patients with familial 
hypercholesterolaemia in primary care: an informatics- based approach in one primary 
care centre. Heart 2008;94:754–8.
 16 Troeung L, Arnold- Reed D, Chan She Ping- Delfos W, et al. A new electronic screening 
tool for identifying risk of familial hypercholesterolaemia in general practice. Heart 
2016;102:855–61.
 17 Kirke AB, Barbour RA, Burrows S, et al. Systematic detection of familial 
hypercholesterolaemia in primary health care: a community based prospective study 
of three methods. Heart Lung Circ 2015;24:250–6.
 18 Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management 
of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 
2020;41:111–88.
 19 Arnold- Reed DE, Brett T, Troeung L, et al. Detection and management of familial 
hypercholesterolaemia in primary care in Australia: protocol for a pragmatic 
cluster intervention study with pre- post intervention comparisons. BMJ Open 
2017;7:e017539.
 20 Humphries SE, Neil HAW. Developing and applying clinically useful approaches 
to identify individuals with familial hypercholesterolemia in the UK. Clin Lipidol 
2010;5:497–507.
 21 Banda JM, Sarraju A, Abbasi F, et al. Finding missed cases of familial 
hypercholesterolemia in health systems using machine learning. NPJ Digit Med 
2019;2:23.
 22 Wald DS, Bestwick JP, Morris JK, et al. Child- parent familial hypercholesterolemia 
screening in primary care. N Engl J Med 2016;375:1628–37.
 23 Weng SF, Kai J, Andrew Neil H, et al. Improving identification of familial 
hypercholesterolaemia in primary care: derivation and validation of the familial 
hypercholesterolaemia case ascertainment tool (FAMCAT). Atherosclerosis 
2015;238:336–43.
 24 Weng S, Kai J, Tranter J, et al. Improving identification and management of 
familial hypercholesterolaemia in primary care: pre- and post- intervention study. 
Atherosclerosis 2018;274:54–60.
 25 Perez de Isla L, Alonso R, Watts GF, et al. Attainment of LDL- cholesterol treatment 
goals in patients with familial hypercholesterolemia: 5- year SAFEHEART registry 
follow- up. J Am Coll Cardiol 2016;67:1278–85.
 26 Hardcastle SJ, Legge E, Laundy CS, et al. Patients’ perceptions and experiences of 
familial hypercholesterolemia, cascade genetic screening and treatment. Int J Behav 
Med 2015;22:92–100.
 27 Weng S, Kai J, Akyea R, et al. Detection of familial hypercholesterolaemia: external 
validation of the FAMCAT clinical case- finding algorithm to identify patients in 
primary care. Lancet Public Health 2019;4:e256–64.
 28 Pang J, Hu M, Lin J, et al. An enquiry based on a standardised questionnaire 
into knowledge, awareness and preferences concerning the care of familial 
hypercholesterolaemia among primary care physicians in the Asia- Pacific region: the 
"Ten Countries Study". BMJ Open 2017;7:e017817.
 29 Ademi Z, Watts GF, Juniper A, et al. A systematic review of economic evaluations 
of the detection and treatment of familial hypercholesterolemia. Int J Cardiol 
2013;167:2391–6.
 30 Green P, Neely D, Humphries SE, et al. Improving detection of familial 
hypercholesterolaemia in primary care using electronic audit and nurse- led clinics. J 
Eval Clin Pract 2016;22:341–8.
 on S
eptem









eart: first published as 10.1136/heartjnl-2020-318813 on 20 M
ay 2021. D
ow
nloaded from
 
